Quick Answer
Krystal Biotech, Inc. reported Net Income Loss of $204.83 million for the year ending 2025.
- Krystal Biotech, Inc. showed an increase of +129.7% in Net Income Loss from 2024 to 2025.
- This data is from Krystal Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Krystal Biotech, Inc.'s Net Income Loss has grown by 17,911.4%.
- Historical annual values: Fiscal year 2025: $204.83 million | Fiscal year 2024: $89.16 million | Fiscal year 2023: $10.93 million | Fiscal year 2022: -$139.98 million | Fiscal year 2021: -$69.57 million | Fiscal year 2020: -$32.17 million | Fiscal year 2019: -$19.09 million | Fiscal year 2018: -$10.89 million | Fiscal year 2017: -$7.92 million | Fiscal year 2016: -$1.15 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: